Partial splenic embolization improves outcomes for cancer patients.

Research indicates that partial splenic embolization (PSE) significantly enhances platelet counts and reduces complications for cancer patients suffering from hypersplenism. Optimal splenic infarction volumes of 388 to 540 ml are essential for achieving these benefits. In cases of massive splenomegaly, the noninfarcted spleen volume is crucial. Additionally, combining PSE with systemic chemotherapy shows promise in prolonging progression-free survival for those with hepatocellular carcinoma while also improving liver function and activating immune responses.